[go: up one dir, main page]

MA40721B1 - Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation - Google Patents

Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Info

Publication number
MA40721B1
MA40721B1 MA40721A MA40721A MA40721B1 MA 40721 B1 MA40721 B1 MA 40721B1 MA 40721 A MA40721 A MA 40721A MA 40721 A MA40721 A MA 40721A MA 40721 B1 MA40721 B1 MA 40721B1
Authority
MA
Morocco
Prior art keywords
interleukin
polypeptide
receptor alpha
methods
fusion proteins
Prior art date
Application number
MA40721A
Other languages
English (en)
Other versions
MA40721A (fr
Inventor
Thomas Malek
Original Assignee
The University Of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40721(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The University Of Miami filed Critical The University Of Miami
Publication of MA40721A publication Critical patent/MA40721A/fr
Publication of MA40721B1 publication Critical patent/MA40721B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)

Abstract

L'invention concerne diverses méthodes et compositions pouvant être utilisées pour moduler le système immunitaire. Les compositions comprennent une protéine de fusion comprenant : (a) un premier polypeptide comprenant l'interleukine-2 (IL-2) ou une variante fonctionnelle ou un fragment de celle-ci ; et (b) un second polypeptide, fusionné dans le cadre du premier polypeptide, le second polypeptide comprenant un domaine extracellulaire du récepteur alpha de l'interleukine-2 (IL-2Rα) ou une variante fonctionnelle ou un fragment de celui-ci, et la protéine de fusion ayant une activité IL-2. L'invention concerne diverses méthodes permettant de moduler la réponse immunitaire chez un sujet, comprenant l'administration à un sujet qui en a besoin d'une quantité thérapeutiquement efficace de la protéine de fusion IL-2/IL-2Rα décrite dans la présente invention.
MA40721A 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation MA40721B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
PCT/US2015/043792 WO2016022671A1 (fr) 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP15750560.3A EP3177307B1 (fr) 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA40721A MA40721A (fr) 2017-06-13
MA40721B1 true MA40721B1 (fr) 2024-08-30

Family

ID=53836871

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40094A MA40094B1 (fr) 2014-08-06 2015-08-04 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
MA40721A MA40721B1 (fr) 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA40094A MA40094B1 (fr) 2014-08-06 2015-08-04 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Country Status (32)

Country Link
US (3) US12084483B2 (fr)
EP (2) EP4438621A3 (fr)
JP (3) JP6723982B2 (fr)
KR (1) KR102653758B1 (fr)
CN (2) CN107074967B (fr)
AU (3) AU2015301071C1 (fr)
BR (1) BR112017001940A2 (fr)
CA (1) CA2957273C (fr)
CL (1) CL2017000284A1 (fr)
CO (1) CO2017002166A2 (fr)
DK (1) DK3177307T3 (fr)
EA (2) EA202091342A3 (fr)
ES (1) ES2986097T3 (fr)
FI (1) FI3177307T3 (fr)
HR (1) HRP20241258T1 (fr)
HU (1) HUE068478T2 (fr)
IL (2) IL250007B (fr)
LT (1) LT3177307T (fr)
MA (2) MA40094B1 (fr)
MX (1) MX388977B (fr)
MY (1) MY180831A (fr)
PE (1) PE20170503A1 (fr)
PH (1) PH12017500042A1 (fr)
PT (1) PT3177307T (fr)
RS (1) RS65930B1 (fr)
SA (1) SA517380842B1 (fr)
SG (2) SG10201913695PA (fr)
SI (1) SI3177307T1 (fr)
SM (1) SMT202400414T1 (fr)
TN (1) TN2017000020A1 (fr)
WO (1) WO2016022671A1 (fr)
ZA (1) ZA201700245B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
NZ719654A (en) 2014-02-06 2020-06-26 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
US12202856B2 (en) 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
JP2019534710A (ja) 2016-09-28 2019-12-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー インターロイキン２に結合する抗体およびその使用
US10961310B2 (en) 2017-03-15 2021-03-30 Pandion Operations, Inc. Targeted immunotolerance
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
EP3746103A4 (fr) * 2017-12-06 2022-03-30 The Board of Trustees of the Leland Stanford Junior University Protéines modifiées pour améliorer la sensibilité d'une cellule à l'il-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019183389A1 (fr) * 2018-03-23 2019-09-26 Kite Pharma, Inc. Protéines transmembranaires chimériques et leurs utilisations
MX2020009975A (es) * 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
MX2021011258A (es) * 2019-03-18 2021-12-10 Biontech Cell & Gene Therapies Gmbh Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activacion especifica de celulas efectoras inmunitarias.
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
WO2020236875A1 (fr) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Immunotolérance ciblée madcam
CN113874390A (zh) * 2019-05-24 2021-12-31 普罗维瓦疗法香港有限公司 Il-2组合物及其使用方法
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
WO2021011353A1 (fr) * 2019-07-12 2021-01-21 Proviva Therapeutics (Hong Kong) Limited Compositions d'il-2 et leurs procédés d'utilisation
CN114466657B (zh) * 2019-07-25 2024-11-15 芝加哥大学 包括蛋白酶激活治疗剂的组合物和方法
US20220378933A1 (en) * 2019-09-19 2022-12-01 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
MX2022004577A (es) * 2019-10-18 2022-05-10 Alkermes Pharma Ireland Ltd Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune.
MX2022007754A (es) 2019-12-20 2022-07-19 Regeneron Pharma Nuevos agonistas de il2 y metodos de uso de estos.
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN115996946A (zh) 2020-04-30 2023-04-21 免疫靶向有限公司 可活化il2组合物和使用方法
CN116194480A (zh) * 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
KR20240149421A (ko) * 2022-02-11 2024-10-14 뮤럴 온콜로지, 인코포레이티드 암 면역요법을 위한 조성물 및 방법
WO2023159135A2 (fr) * 2022-02-16 2023-08-24 University Of Miami Protéines de fusion il-2 et tl1a et leurs procédés d'utilisation
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
AU2024224039A1 (en) * 2023-02-22 2025-06-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-il2ra antibodies and uses thereof
WO2025207491A1 (fr) * 2024-03-25 2025-10-02 Mural Oncology, Inc. Compositions et méthodes pour immunothérapie anticancéreuse

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
AU704829B2 (en) 1994-12-28 1999-05-06 University Of Kentucky Murine anti-idiotype antibody 3H1
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
JPWO2003029475A1 (ja) 2001-09-28 2005-01-20 株式会社ディナベック研究所 エピトープ結合β２ｍをコードする哺乳動物細胞感染性ウイルスベクターおよびその利用
CA2557677A1 (fr) 2004-03-05 2005-10-06 Chiron Corporation Systeme de tests in vitro permettant de predire la tolerabilite d'agents therapeutiques chez des patients
EP3263581B2 (fr) 2005-05-17 2025-07-09 University of Connecticut Compositions et procédés d'immunomodulation dans un organisme
CN101255197B (zh) 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP2553101A4 (fr) * 2010-04-02 2013-09-04 Univ Rochester Cytokines activées par des protéases
WO2012088383A2 (fr) 2010-12-23 2012-06-28 Genentech, Inc. Interactions pilr alpha et procédés visant à les modifier
CA2869674A1 (fr) 2012-06-08 2013-12-12 Alkermes, Inc. Polypeptides hybrides comprenant une proteine active liee a un polypeptide a domaine mucin
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (fr) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Amélioration de la demi-vie d'un polypeptide thérapeutique par fusion avec une protéine d'échafaudage trimère via un espaceur
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
NZ766851A (en) 2024-07-26
PE20170503A1 (es) 2017-05-11
JP7272663B2 (ja) 2023-05-12
HRP20241258T1 (hr) 2024-12-06
CN107074967A (zh) 2017-08-18
SG10201913695PA (en) 2020-03-30
SG11201700706WA (en) 2017-02-27
JP2023099045A (ja) 2023-07-11
JP2021000084A (ja) 2021-01-07
US20250163118A1 (en) 2025-05-22
US20230079120A1 (en) 2023-03-16
SMT202400414T1 (it) 2024-11-15
ZA201700245B (en) 2024-06-26
KR102653758B1 (ko) 2024-04-04
MA40721A (fr) 2017-06-13
SI3177307T1 (sl) 2024-09-30
EP3177307B1 (fr) 2024-07-17
MX388977B (es) 2025-03-20
AU2022204034A1 (en) 2022-07-14
AU2020203352A1 (en) 2020-07-02
AU2020203352B2 (en) 2022-03-10
WO2016022671A1 (fr) 2016-02-11
TN2017000020A1 (en) 2018-07-04
PH12017500042A1 (en) 2017-05-22
AU2015301071A1 (en) 2017-02-02
EP3177307A1 (fr) 2017-06-14
SA517380842B1 (ar) 2021-12-26
EP4438621A3 (fr) 2024-12-18
FI3177307T3 (fi) 2024-10-04
MA40094B1 (fr) 2022-05-31
NZ728042A (en) 2024-07-26
CL2017000284A1 (es) 2017-11-17
RS65930B1 (sr) 2024-10-31
AU2015301071B2 (en) 2020-03-05
CN113912737A (zh) 2022-01-11
DK3177307T3 (da) 2024-10-07
PT3177307T (pt) 2024-09-13
MX2017001062A (es) 2017-07-14
JP2017523789A (ja) 2017-08-24
CA2957273C (fr) 2023-03-14
US20170233448A1 (en) 2017-08-17
ES2986097T3 (es) 2024-11-08
AU2015301071C1 (en) 2020-07-02
EA035956B1 (ru) 2020-09-04
CN107074967B (zh) 2021-06-08
MY180831A (en) 2020-12-10
US12084483B2 (en) 2024-09-10
EP4438621A2 (fr) 2024-10-02
EA202091342A3 (ru) 2020-12-30
MA40094A1 (fr) 2021-09-30
CA2957273A1 (fr) 2016-02-11
IL250007A0 (en) 2017-03-30
LT3177307T (lt) 2024-08-12
EA201790063A1 (ru) 2017-06-30
EA202091342A2 (ru) 2020-11-30
HUE068478T2 (hu) 2025-01-28
CO2017002166A2 (es) 2017-05-19
BR112017001940A2 (pt) 2017-11-28
IL250007B (en) 2020-07-30
JP6723982B2 (ja) 2020-07-15
KR20170030646A (ko) 2017-03-17
IL275944A (en) 2020-08-31
IL275944B (en) 2022-02-01

Similar Documents

Publication Publication Date Title
MA40721B1 (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
CY1123783T1 (el) Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου
MX2021007925A (es) Inhibidores irreversibles de la interaccion menina-mll.
MY202480A (en) Fusion protein containing tgf- receptor and medicinal uses thereof
MX2021008144A (es) Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
MA50949B1 (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MX386014B (es) Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
PE20181338A1 (es) Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
MX2021003475A (es) Metodos de purificacion de proteinas.
EA201991207A1 (ru) Новые агонисты tnfr и их применение
MX2021000083A (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
BR112022001575A2 (pt) Formulações de anticorpos anti-pvrig e usos dos mesmos
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
EP4223784A3 (fr) Compositions et procédés pour moduler une réponse immunitaire à médiation par des lymphocytes t
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MX2020007628A (es) Composiciones y metodos de uso.
JOP20210326A1 (ar) أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
CR20220322A (es) Formulaciones de anticuerpos anti-pd-l1
BR112021014566A2 (pt) Moduladores de gpr35
MX2020012016A (es) Sistemas y metodos para cuantificar y modificar la viscosidad de proteinas.
ZA202005875B (en) Lfa3 variants and compositions and uses thereof
EP3888692A4 (fr) Inhibiteur de protéine interagissant avec la striatine et son utilisation dans la préparation d'un médicament anti-tumoral
MX2020011814A (es) Anticuerpo anti-tlr7 humano.